BioTheryX Doses First Patient in Phase 1 Study Investigating Lead Protein Degrader Candidate BTX-1188

Last Updated on September 29, 2022 by biotheryx

Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of BTX-1188 in Patients with Advanced Hematologic and Solid Tumor Malignancies

SAN DIEGO, Jan. 26, 2022 — BioTheryX, Inc., a clinical-stage company focused on developing targeted protein degraders to create life-saving medicines, today announced dosing of the first patient in a new, first-in human Phase 1 study investigating its lead candidate BTX-1188, an oral, dual target protein degrader specifically engineered to degrade GSPT1 and IKZF1/3, in patients with advanced hematologic and solid tumor malignancies.

“BTX-1188 has demonstrated rapid, deep and durable degradation of both GSPT1 and IKZF1/3 at low nanomolar concentrations in preclinical models, and we are delighted to make this exciting advancement into the clinic,” said Zung Thai, M.D., Ph.D., Chief Medical Officer of BioTheryX. “We are grateful to our clinical trial site partners for initiating this study in these challenging times and thank them for their commitment to investigating potential new therapeutic options for people facing difficult-to-treat cancers.”

The Phase 1 clinical trial is a multicenter, open label, non-randomized, sequential dose escalation study to assess the safety, pharmacokinetics and preliminary efficacy of BTX-1188 in patients with acute myeloid leukemia, advanced lymphoid and solid tumors who have failed standard therapy. The primary objective of the Phase 1 study is to determine a recommended Phase 2 dose, which will then be carried forward into expansion cohorts where the safety and efficacy of BTX-1188 will be evaluated in both hematologic and solid tumor malignancies. More information can be found on clinicaltrials.gov (NCT05144334).

“BTX-1188 is one of many potential best-in-class protein degrader candidates our team has designed and developed leveraging our distinctive PRODEGY targeted protein degradation platform to provide new treatment approaches for people living with cancer and other diseases,” said Philippe Drouet, President and Chief Executive Officer of BioTheryX. “With our clinical trial site partners, we are working as expeditiously as possible to study BTX-1188 and validate the potential of our platform.”

About BTX-1188

BTX-1188 is the first orally bioavailable, rationally designed dual target protein degrader, engineered to specifically degrade validated oncology targets GSPT1 and IKZF1/3. By degrading GSPT1 and IKZF1/3, BTX-1188’s profile is expected to be differentiated from protein degraders that exclusively target GSPT1. Preclinical data for BTX-1188 has shown rapid, deep and durable degradation of these targets at low nanomolar concentrations. Acute myeloid leukemia (AML) xenograft experiments have also shown significant decreases in tumor volume and increased survival compared to controls and other degraders of GSPT1. BioTheryX believes BTX-1188 has broad potential applicability in both hematologic and solid tumor malignancies and is currently studying the molecule in both settings as part of a Phase 1 clinical study.

About BioTheryX, Inc.

BioTheryX is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from cancer, inflammatory and immunological diseases through the discovery, development and commercialization of targeted protein degradation therapies. We leverage our proprietary PRODEGY technology platform and differentiated targeted protein degradation approach to design small molecules that regulate protein homeostasis. We believe our approach is applicable to a broad range of diseases and has the potential to target proteins that have historically been considered undruggable. Our initial programs are focused on oncology indications with high unmet medical need. For more information, please visit www.biotheryx.com and engage with us on LinkedIn.

Contacts:

Investors/Media
212.600.1902
[email protected]

BioTheryX Announces Appointment of Sahm Nasseri as Chief Business Officer

Last Updated on September 29, 2022 by biotheryx

SAN DIEGO, Jan. 20, 2022 — BioTheryX, Inc., a clinical-stage company focused on targeted protein degradation to create life-saving medicines, today announced the appointment of Sahm Nasseri as Chief Business Officer.

“Sahm is an accomplished biopharma leader with impressive experience in business development, corporate strategy, commercialization and program management. His expertise and leadership, most recently growing the U.S operations of an international biotech company and previously leading global commercial franchises for Merck, will help advance our pipeline of best-in-class protein degraders,” said Philippe Drouet, President and Chief Executive Officer of BioTheryX. “As the company’s first Chief Business Officer, Sahm will play an important role in establishing relationships with potential collaborators as we continue to expand our research and development programs.”

Mr. Nasseri previously served as Chief Executive Officer of PYC Therapeutics, an RNA therapeutics company based in the United States and Australia, where he built out the Company’s U.S. presence and preclinical, clinical and corporate development teams. Prior to this, Mr. Nasseri served at Merck & Co for seven years as a leader across business development, investor relations and corporate strategy functions where he gained extensive commercial drug development experience. He led global strategy for Merck’s growing oncology organization and served as interim Vice President and Global Product Leader for Merck’s HPV Vaccines, a family of vaccines with over $4 billion in annual revenue. Before Merck, Mr. Nasseri worked as a strategy consultant for McKinsey & Company. Mr. Nasseri holds a Bachelor of Chemical Engineering from the University of New South Wales in Sydney and an MBA from Columbia Business School in New York City.

“The outstanding team at BioTheryX has spent years building the leading targeted protein degradation platform in the industry. This PRODEGY platform is now poised to make a significant impact on patients with cancer with the lead protein degrader program entering Phase 1 clinical trials,” said Mr. Nasseri. “I am passionate about bridging great science towards the efficient development of medicines that can address important unmet patient needs and as such, I am excited to join BioTheryX and support the ongoing growth of the company and the continued development of its pipeline of first-in-class and best-in-class protein degradation therapies.”

About BioTheryX, Inc.

BioTheryX is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from cancer, inflammatory and immunological diseases through the discovery, development and commercialization of targeted protein degradation therapies. We leverage our proprietary PRODEGY technology platform and differentiated targeted protein degradation approach to design small molecules that regulate protein homeostasis. We believe our approach is applicable to a broad range of diseases and has the ability to address protein targets that have historically been considered undruggable. Our initial programs are focused on oncology indications with high unmet medical need. For more information, please visit www.biotheryx.com and engage with us on LinkedIn.

Contacts:

Investors/Media
[email protected]